Arcus Biosciences, Inc.RCUSNYSE
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +50.00% | -16.13% | -80.69% | +310.26% | -45.83% |
| Gross Profit Growth | +50.00% | -16.13% | -80.69% | +310.26% | -50.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +22.52% | +22.27% | +14.15% | +16.47% | +16.52% |
| Weighted Average Shares Diluted Growth | +22.52% | +22.27% | +14.15% | +16.90% | +16.52% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -473.08% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -488.00% |
| Receivables Growth | -62.50% | -40.48% | -47.50% | -39.39% | -33.33% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +5.12% | +5.02% | -10.60% | -9.36% | -22.20% |
| Book Value per Share Growth | -11.32% | -14.14% | -34.21% | -25.77% | -33.77% |
| Debt Growth | +544.44% | +445.45% | +445.45% | +890.91% | +91.38% |
| R&D Expense Growth | +50.00% | +8.60% | +11.93% | +20.87% | +14.63% |
| SG&A Expenses Growth | +0.00% | -3.45% | -12.50% | -3.33% | -10.00% |